Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Oestrogen inhibition reverses pulmonary arterial hypertension and associated metabolic defects.

The European respiratory journal - 1 Aug 2017

Chen Xinping, Austin Eric D, Talati Megha, Fessel Joshua P, Farber-Eger Eric H, Brittain Evan L, Hemnes Anna R, Loyd James E, West James

Abstract excerpt

Increased oestrogen is a strong epidemiological risk factor for development of pulmonary arterial hypertension (PAH) in patients, associated with metabolic defects. In addition, oestrogens drive penetrance in mice carrying mutations in bone morphogenetic protein receptor type II (BMPR2), the cause of most heritable PAH. The goal of the present study was to determine whether inhibition of oestrogens was effective...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bone Morphogenetic Protein Receptors, Type II
Share to Estrogen Antagonists

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Fulvestrant

Share to Hemodynamics

Share to Hypertension, Pulmonary

Share to Nitriles

Share to Tamoxifen

Share to Triazoles

Source

Open in PubMed Open full text

Identifiers

PMID: 28775043
DOI: 10.1183/13993003.02337-2016
PMCID: PMC6532788

Genes

PAH
BMPR2
ESR2
ESR1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Oestrogen inhibition reverses pulmonary arterial hypertension and associated metabolic defects.PMID 28775043Read ↗

Interaction between Bone Morphogenetic Protein Receptor Type 2 and Estrogenic Compounds in Pulmonary Arterial HypertensionSemantic proximity Read ↗

Alterations in oestrogen metabolism: implications for higher penetrance of familial pulmonary arterial hypertension in females.Semantic proximity Read ↗

BMPR2 Mutation and Metabolic Reprogramming in Pulmonary Arterial Hypertension.Semantic proximity Read ↗

Effective treatments for PAH will require detailed knowledge of molecular aetiology.Semantic proximity Read ↗

Novel Advances in Modifying BMPR2 Signaling in PAHSemantic proximity Read ↗

The Role of Sex in the Pathophysiology of Pulmonary Hypertension.Semantic proximity Read ↗

BMPR2 expression is suppressed by signaling through the estrogen receptorSemantic proximity Read ↗

Sex-linked Lung Estrobolome May Contribute to Pulmonary Hypertension Penetrance of <i>Bmpr2 R899X</i> Mutation via an ET-1 <sup>high</sup> Endoregulatory Macrophage PhenotypeSemantic proximity Read ↗

Hypoxia‐induced pulmonary hypertension upregulates eNOS and TGF‐β contributing to sex‐linked differences in BMPR2+/R899X mutant miceSemantic proximity Read ↗

Anticipated Classes of New Medications and Molecular Targets for Pulmonary Arterial HypertensionSemantic proximity Read ↗

Increased susceptibility to pulmonary hypertension in heterozygous BMPR2-mutant mice.Semantic proximity Read ↗

Epoxyeicosatrienoic acid agonist rescues the metabolic syndrome phenotype of HO-2-null mice.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.